ImmunoGen, Novartis in cancer deal

ImmunoGen Inc. (NASDAQ:IMGN) partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop cancer therapeutics using ImmunoGen's Targeted Antibody Payload (TAP) technology. The therapeutics will consist of antibodies against targets selected by Novartis linked to a cytotoxic anti-cancer agent from ImmunoGen using the TAP technology. ...